{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T11:01:21Z","timestamp":1791975681610,"version":"4.4.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:00:00Z","timestamp":1761091200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008129","name":"Helsinn Group Headquarters","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008129","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.annonc.2025.10.017","type":"journal-article","created":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T14:39:27Z","timestamp":1760711967000},"page":"260-270","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Personalised antiemetic prophylaxis with NEPA for patients at high risk of chemotherapy-induced nausea and vomiting receiving moderately emetogenic chemotherapy: results from the randomised, multinational MyRisk trial"],"prefix":"10.1016","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6351-9991","authenticated-orcid":false,"given":"A.","family":"Molassiotis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9379-5938","authenticated-orcid":false,"given":"K.","family":"Jordan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Karthaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Dranitsaris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.J.","family":"Roeland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7433-3428","authenticated-orcid":false,"given":"L.","family":"Schwartzberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Stimamiglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0123-8160","authenticated-orcid":false,"given":"A.","family":"Alonzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Olivari Tilola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Bonizzoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Brozos V\u00e1zquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6667-994X","authenticated-orcid":false,"given":"T.","family":"Buchler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3151-6427","authenticated-orcid":false,"given":"D.C.","family":"Christoph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Garc\u00eda Alfonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Majem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Mavroudis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Syrigos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Tomlins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Zimovjanov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Aapro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"14","key":"10.1016\/j.annonc.2025.10.017_bib1","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1056\/NEJMra1515442","article-title":"Antiemetic prophylaxis for chemotherapy-induced nausea and vomiting","volume":"374","author":"Navari","year":"2016","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.annonc.2025.10.017_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.102195","article-title":"2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting","volume":"9","author":"Herrstedt","year":"2024","journal-title":"ESMO Open"},{"issue":"24","key":"10.1016\/j.annonc.2025.10.017_bib4","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1200\/JCO.20.01296","article-title":"Antiemetics: ASCO guideline update","volume":"38","author":"Hesketh","year":"2020","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2025.10.017_bib5","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1200\/JCO.1997.15.1.103","article-title":"Proposal for classifying the acute emetogenicity of cancer chemotherapy","volume":"15","author":"Hesketh","year":"1997","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.annonc.2025.10.017_bib6","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1093\/annonc\/mdx100","article-title":"The development of a prediction tool to identify cancer patients at high risk for chemotherapy-induced nausea and vomiting","volume":"28","author":"Dranitsaris","year":"2017","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.annonc.2025.10.017_bib7","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.jpainsymman.2013.06.012","article-title":"Evaluation of risk factors predicting chemotherapy-related nausea and vomiting: results from a European prospective observational study","volume":"47","author":"Molassiotis","year":"2014","journal-title":"J Pain Symptom Manage"},{"key":"10.1016\/j.annonc.2025.10.017_bib8","doi-asserted-by":"crossref","first-page":"283","DOI":"10.2147\/CMAR.S447546","article-title":"Risk factors associated with chemotherapy-induced nausea and vomiting among women with breast cancer receiving highly emetogenic chemotherapy: individual patient-based analysis of three prospective antiemetic trials","volume":"16","author":"Yeo","year":"2024","journal-title":"Cancer Manag Res"},{"issue":"1","key":"10.1016\/j.annonc.2025.10.017_bib9","first-page":"45","article-title":"2023 updated MASCC\/ESMO Consensus recommendations: prevention of nausea and vomiting following moderately emetic risk antineoplastic agents","volume":"32","author":"Scott\u00e9","year":"2023","journal-title":"Support Care Cancer"},{"issue":"1","key":"10.1016\/j.annonc.2025.10.017_bib10","first-page":"21","article-title":"Is the addition of a neurokinin-1 receptor antagonist beneficial in moderately emetogenic chemotherapy?\u2014a systematic review and meta-analysis","volume":"26","author":"Jordan","year":"2018","journal-title":"Support Care Cancer"},{"issue":"suppl 12","key":"10.1016\/j.annonc.2025.10.017_bib11","article-title":"Model-predicted neurokinin-1 (NK1) receptor occupancy of netupitant versus aprepitant over an extended time period: implications for controlling nausea and vomiting associated with antibody-drug conjugates (ADCs)","volume":"31","author":"Aapro","year":"2025","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.annonc.2025.10.017_bib12","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1007\/s00221-014-4017-7","article-title":"Netupitant and palonosetron trigger NK1 receptor internalization in NG108-15 cells","volume":"232","author":"Thomas","year":"2014","journal-title":"Exp Brain Res"},{"issue":"8","key":"10.1016\/j.annonc.2025.10.017_bib13","first-page":"522","article-title":"Assessing the impact of chemotherapy-induced nausea and vomiting on patients\u2019 daily lives: a modified version of the Functional Living Index-Emesis (FLIE) with 5-day recall.","volume":"11","author":"Martin","year":"2003","journal-title":"Support Care Cancer"},{"issue":"1","key":"10.1016\/j.annonc.2025.10.017_bib14","first-page":"35","article-title":"Measuring the maintenance of daily life activities using the functional living index-emesis (FLIE) in patients receiving moderately emetogenic chemotherapy","volume":"4","author":"Decker","year":"2006","journal-title":"J Support Oncol"},{"issue":"2","key":"10.1016\/j.annonc.2025.10.017_bib15","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jpainsymman.2006.10.018","article-title":"Validation and psychometric assessment of a short clinical scale to measure chemotherapy-induced nausea and vomiting: the MASCC antiemesis tool","volume":"34","author":"Molassiotis","year":"2007","journal-title":"J Pain Symptom Manage"},{"key":"10.1016\/j.annonc.2025.10.017_bib16","series-title":"Common terminology criteria for adverse events (CTCAE) v5.0. 2025","year":"2017"},{"key":"10.1016\/j.annonc.2025.10.017_bib17","doi-asserted-by":"crossref","first-page":"400","DOI":"10.3389\/fonc.2020.00400","article-title":"Expert consensus on effective management of chemotherapy-induced nausea and vomiting: an Indian perspective","volume":"10","author":"Vaid","year":"2020","journal-title":"Front Oncol"},{"issue":"6","key":"10.1016\/j.annonc.2025.10.017_bib18","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1111\/cas.12146","article-title":"Risk factors of chemotherapy-induced nausea and vomiting: index for personalized antiemetic prophylaxis","volume":"104","author":"Sekine","year":"2013","journal-title":"Cancer Sci"},{"issue":"11","key":"10.1016\/j.annonc.2025.10.017_bib19","doi-asserted-by":"crossref","first-page":"4928","DOI":"10.1007\/s12325-023-02648-1","article-title":"Pooled analysis of studies evaluating fosnetupitant and risk factors for cisplatin-induced nausea and vomiting during the extended overall phase","volume":"40","author":"Inui","year":"2023","journal-title":"Adv Ther"},{"issue":"3","key":"10.1016\/j.annonc.2025.10.017_bib20","first-page":"1139","article-title":"Risk factors associated with chemotherapy-induced nausea and vomiting in the triplet antiemetic regimen including palonosetron or granisetron for cisplatin-based chemotherapy: analysis of a randomized, double-blind controlled trial","volume":"27","author":"Tsuji","year":"2019","journal-title":"Support Care Cancer"},{"issue":"6","key":"10.1016\/j.annonc.2025.10.017_bib21","doi-asserted-by":"crossref","first-page":"414","DOI":"10.3747\/co.19.1074","article-title":"Prospective validation of risk prediction indexes for acute and delayed chemotherapy-induced nausea and vomiting","volume":"19","author":"Bouganim","year":"2012","journal-title":"Curr Oncol"},{"key":"10.1016\/j.annonc.2025.10.017_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.artmed.2020.101925","article-title":"A dynamic prediction engine to prevent chemotherapy-induced nausea and vomiting","volume":"109","author":"Mosa","year":"2020","journal-title":"Artif Intell Med"},{"issue":"10","key":"10.1016\/j.annonc.2025.10.017_bib23","first-page":"2759","article-title":"Development and preliminary validation of a risk prediction model for chemotherapy-related nausea and vomiting","volume":"21","author":"Molassiotis","year":"2013","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.annonc.2025.10.017_bib24","author":"Dranitsaris"},{"issue":"4","key":"10.1016\/j.annonc.2025.10.017_bib25","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1055\/s-0041-1726136","article-title":"Chemotherapy-induced nausea and vomiting (CINV) with GI cancer chemotherapy: do we need CINV risk score over and above antiemetic guidelines in prescribing antiemetic regime?","volume":"9","author":"D\u2019Souza","year":"2020","journal-title":"South Asian J Cancer"},{"issue":"2","key":"10.1016\/j.annonc.2025.10.017_bib26","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1001\/jamaoncol.2015.3730","article-title":"Risk model-guided antiemetic prophylaxis vs physician\u2019s choice in patients receiving chemotherapy for early-stage breast cancer: a randomized clinical trial","volume":"2","author":"Clemons","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.annonc.2025.10.017_bib27","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.breast.2020.11.002","article-title":"A randomized trial of individualized versus standard of care antiemetic therapy for breast cancer patients at high risk for chemotherapy-induced nausea and vomiting","volume":"54","author":"Clemons","year":"2020","journal-title":"Breast"},{"issue":"3","key":"10.1016\/j.annonc.2025.10.017_bib29","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1093\/oncolo\/oyac240","article-title":"Duration of chemotherapy-induced nausea and vomiting (CINV) as a predictor of recurrent CINV in later cycles","volume":"28","author":"Navari","year":"2023","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.annonc.2025.10.017_bib30","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1007\/s10147-016-1022-9","article-title":"Combination antiemetic therapy with aprepitant\/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy in the SENRI trial: analysis of risk factors for vomiting and nausea","volume":"22","author":"Takemoto","year":"2017","journal-title":"Int J Clin Oncol"},{"issue":"4","key":"10.1016\/j.annonc.2025.10.017_bib31","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.5250","article-title":"Effect of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in women: a randomized clinical trial","volume":"4","author":"Wang","year":"2021","journal-title":"JAMA Network Open"},{"issue":"19","key":"10.1016\/j.annonc.2025.10.017_bib32","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.2217\/fon-2017-0712","article-title":"Optimal prophylaxis of chemotherapy-induced nausea and vomiting for moderately emetogenic chemotherapy: a meta-analysis","volume":"14","author":"Zhang","year":"2018","journal-title":"Future Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2025.10.017_bib33","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.annonc.2024.09.001","volume":"36","author":"Sakai","year":"2025","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2025.10.017_bib34","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.annonc.2024.10.017","article-title":"Beyond the usual window: persistent nausea with trastuzumab deruxtecan calls for new management strategies","volume":"36","author":"Jordan","year":"2025","journal-title":"Ann Oncol"},{"issue":"suppl 1","key":"10.1016\/j.annonc.2025.10.017_bib35","article-title":"Individual patient data meta-analysis of NEPA versus aprepitant antiemetic regimens in the prevention of chemotherapy-induced nausea and vomiting (CINV)","volume":"32","author":"Navari","year":"2024","journal-title":"Support Care Cancer"},{"issue":"23","key":"10.1016\/j.annonc.2025.10.017_bib36","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.2217\/fon-2021-0023","article-title":"Single-dose netupitant\/palonosetron versus 3-day aprepitant for preventing chemotherapy-induced nausea and vomiting: a pooled analysis","volume":"17","author":"Navari","year":"2021","journal-title":"Future Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2025.10.017_bib37","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s40487-022-00188-2","article-title":"Exploratory analysis comparing fosnetupitant versus fosaprepitant for prevention of highly emetogenic chemotherapy-induced nausea and vomiting (CINV): a randomized, double-blind, phase 3 study (CONSOLE)","volume":"10","author":"Hata","year":"2022","journal-title":"Oncol Ther"},{"issue":"15","key":"10.1016\/j.annonc.2025.10.017_bib38","doi-asserted-by":"crossref","first-page":"15769","DOI":"10.1002\/cam4.6121","article-title":"Single-dose NEPA versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy","volume":"12","author":"Zelek","year":"2023","journal-title":"Cancer Med"},{"issue":"1","key":"10.1016\/j.annonc.2025.10.017_bib39","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1093\/annonc\/mdx757","article-title":"European Society for Medical Oncology (ESMO) position paper on supportive and palliative care","volume":"29","author":"Jordan","year":"2018","journal-title":"Ann Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753425049646?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753425049646?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T21:06:58Z","timestamp":1773868018000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753425049646"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S0923753425049646"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2025.10.017","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Personalised antiemetic prophylaxis with NEPA for patients at high risk of chemotherapy-induced nausea and vomiting receiving moderately emetogenic chemotherapy: results from the randomised, multinational MyRisk trial","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2025.10.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}]}}